Developmental and epileptic encephalopathies after successful treatment of pediatric ALL: A case series and review of literature
2024

Epileptic Encephalopathies After Treatment of Pediatric ALL

Sample size: 4 publication Evidence: low

Author Information

Author(s): Shukla Vanita, Cheng Sylvia, Hukin Juliette, Huh Linda, Datta Anita N.

Primary Institution: BC Children's Hospital, University of British Columbia

Hypothesis

Is there a link between successful treatment of pediatric acute lymphoblastic leukemia (ALL) and the development of drug-resistant epileptic encephalopathies?

Conclusion

Successful treatment of childhood ALL is rarely associated with the development of drug-resistant epileptic encephalopathies, and young age at diagnosis may be a predisposing factor.

Supporting Evidence

  • Three of the four patients experienced symptomatic methotrexate neurotoxicity during treatment.
  • All patients developed drug-resistant epileptic encephalopathies and moderate intellectual disability.
  • Young age at ALL diagnosis (<3 years) may be a predisposing factor for developing drug-resistant epilepsy.

Takeaway

Some kids who get treated for leukemia can later have serious seizures that are hard to control, especially if they were very young when they got sick.

Methodology

Clinical data were collected via chart review of four patients who developed drug-resistant epileptic encephalopathies after treatment for ALL.

Limitations

The study is based on a small sample size and lacks genetic predisposition testing for all patients.

Participant Demographics

All participants were pediatric patients diagnosed with acute lymphoblastic leukemia, with a mean age of 1.9 years at diagnosis.

Digital Object Identifier (DOI)

10.1002/epd2.20280

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication